Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.
ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.
The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.
The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.
ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.
Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.
Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.
For more information, visit ProPhase Labs.
ProPhase Labs, Inc. (NASDAQ: PRPH) has announced a new stock repurchase program of up to $6 million. This decision follows the expiration of the previous buyback program in February 2023. Over the last six months, ProPhase has retired 1.2 million shares. The new buyback will occur over the next six months and will depend on various factors, including market conditions. CEO Ted Karkus emphasized the company's strong execution over the past two years, highlighting growth in subsidiaries such as Pharmaloz and Nebula Genomics with expected revenue increases. The development of the BE-Smart Esophageal Cancer Test is also progressing well, with a potential launch later this year.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced a significant presentation at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting from March 11-16, 2023, in New Orleans, LA. The presentation will showcase the BE-Smart Test, which detects precancerous conditions in Barrett's esophagus, a notable concern given the rapid rise of esophageal adenocarcinoma in the U.S. The senior author, Dr. Andrew Cannon from the Mayo Clinic, will present findings that demonstrate the BE-Smart Test's effectiveness with over 99% accuracy. The test aims to facilitate early cancer detection, potentially reducing late-stage diagnoses, with commercialization plans underway.
ProPhase Labs (NASDAQ: PRPH) announced a significant update regarding its subsidiary, Nebula Genomics, which has launched a new whole genome sequencing (WGS) test priced at only $249. This price is notably lower than competing services that range from $400 to $1100, positioning Nebula as a leading player in the direct-to-consumer genomics market. The WGS service decodes approximately 6.4 billion base pairs and offers over 300 personalized reports based on genetic profiles. Furthermore, Nebula's state-of-the-art laboratory in New York enhances service efficiency and accuracy, showcasing ProPhase's commitment to accessible personal genomics.
ProPhase Labs (NASDAQ: PRPH) has announced a collaboration with mProbe, Inc. and Dr. Christopher Hartley of Mayo Clinic to develop the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test. Initial commercialization is targeted for Q3 2023 as a laboratory developed test, with full commercialization expected by mid-2024. The test has demonstrated over 99% accuracy in identifying significant histologic classifications and aims to aid in early detection of esophageal cancer. ProPhase estimates a potential market of $2 billion to $4 billion based on annual endoscopies for Barrett’s esophagus.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced the initiation of a randomized clinical trial for Equivir, aiming for commercial launch in Q4 2023. Conducted by Vedic Lifesciences at 12 sites, enrollment starts March 2023. CEO Ted Karkus emphasizes the potential of Equivir to improve health outcomes globally. Following a licensing deal in Q2 2022, ProPhase has developed Equivir's formulation and marketing plans. The trial is expected to conclude in Q3 2023, with Equivir designed to block viral entry into cells, leveraging the company's extensive retail partnerships for distribution.
ProPhase Labs (NASDAQ: PRPH) has announced that its diagnostic test for esophageal cancer screening, the BE-Smart assay, was featured in the International Journal of Molecular Science. The assay aims to address the limitations of current diagnostic protocols, demonstrating over 99% sensitivity and specificity in identifying high-risk cancerous protein expressions.
The company plans to commercialize the BE-Smart test within 12 to 18 months, targeting a multi-billion-dollar market. CEO Ted Karkus emphasized its potential to improve early detection of precancerous cells, significantly enhancing patient outcomes.
ProPhase Labs, Inc. (NASDAQ: PRPH) recently announced business updates regarding its subsidiary, Pharmaloz Manufacturing. The company is set to acquire new equipment to double pouch packaging capacity by Q2 2023 and aims for a total capacity increase of 200% by 2024. This expansion will be funded through internal cash flow, requiring no capital from the parent company. In 2022, Pharmaloz took on two new full-production customers and launched seven new products. Furthermore, negotiations are underway with potential clients that could significantly boost production. CEO Ted Karkus emphasized the company's growth strategy and solid partnerships with major retailers.
ProPhase Labs (NASDAQ: PRPH) provided a progress report on its cancer co-therapy program, Linebacker-1 (LB-1), developed by its subsidiary ProPhase BioPharma. LB-1 targets PIM kinase receptors and is designed to enhance traditional chemotherapy effectiveness while reducing toxicity. The company collaborated with Dana-Farber Cancer Institute to explore effective combinations with LB-1, focusing on various cancer types. Initial studies show promising results, with plans for animal studies to complete by Q2 2023 and IND application submission targeted for mid-2024. Development costs are estimated between $3 million and $5 million.
ProPhase Labs (NASDAQ: PRPH) has successfully acquired exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic test from Stella Diagnostics for approximately $4.6 million. This test aims to enhance early detection of esophageal cancer and is expected to reduce unnecessary endoscopies. The BE-Smart test has shown over 99% sensitivity and specificity in preliminary trials. ProPhase anticipates commercializing the test within 18 months and targets reimbursement rates between $1,000 - $3,000, addressing a multi-billion dollar market in the U.S.
ProPhase Labs (NASDAQ: PRPH) has entered into an asset purchase agreement to acquire world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic test from Stella Diagnostics for approximately $4.5 million in cash and stock. An additional $2 million may be issued based on future revenue milestones. The BE-Smart test, showing over 99% sensitivity and specificity, aims for early esophageal cancer detection and could reduce unnecessary endoscopies. The acquisition is pending Stella shareholders' approval and is expected to close in early January 2023.
FAQ
What is the current stock price of ProPhase Labs (PRPH)?
What is the market cap of ProPhase Labs (PRPH)?
What does ProPhase Labs, Inc. do?
What are the main segments of ProPhase Labs' operations?
What services does the Diagnostic Services segment provide?
What products are offered in the Consumer Products segment?
What is the BE-Smart Esophageal Cancer Test?
What recent projects has ProPhase Labs undertaken?
How does ProPhase Labs engage with its investors?
How does ProPhase Labs contribute to healthcare?
